Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

Transplant International

Volumn 27, Issue 4, 2014, Pages 391-398

  Shindoh, Junichi ^a   Sugawara, Yasuhiko ^a   Nagata, Rihito ^a   Kaneko, Junichi ^a   Tamura, Sumihito ^a   Aoki, Taku ^a   Sakamoto, Yoshihiro ^a   Hasegawa, Kiyoshi ^a   Tanaka, Tomohiro ^b   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

alpha fetoprotein; des gamma carboxyprothrombin; hepatocellular carcinoma; liver transplantation; neutrophil lymphocyte ratio; tumor markers

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; AFP PROTEIN, HUMAN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; STATISTICAL PARAMETERS; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; VIRUS HEPATITIS; BLOOD; CARCINOMA, HEPATOCELLULAR; LEUKOCYTE COUNT; LIVER NEOPLASMS; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RISK;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LEUKOCYTE COUNT; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84899424525     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12274     Document Type: Article

References (34)

1. Fujiki M, Takada Y, Ogura Y, et al,. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362.
2. Han K, Tzimas GN, Barkun JS, et al,. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39.
3. Shimada M, Yonemura Y, Ijichi H, et al,. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc 2005; 37: 1177.
4. Taketomi A, Sanefuji K, Soejima Y, et al,. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531.
5. Vibert E, Azoulay D, Hoti E, et al,. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129.
6. Halazun KJ, Hardy MA, Rana AA, et al,. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141.
7. Motomura T, Shirabe K, Mano Y, et al,. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58.
8. Mano Y, Shirabe K, Yamashita Y, et al,. Preoperative neutrophil-to- lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013; 258: 301.
9. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J,. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transplant Int 2013; 27: 32.
10. Sapisochin G, Yao FY, Roberts JP,. Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma? Ann Surg 2011; 254: 383.
11. Lee E, Edward S, Singal AG, Lavieri MS, Volk M,. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol 2013; 11: 437.
12. Chen TM, Huang PT, Tsai MH, et al,. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22: 669.
13. Deyashiki Y, Nishioka Y, Takahashi K, Kosaka Y, Suzuki K,. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma. Cancer 1989; 64: 2546.
14. Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M,. Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transplant 2005; 5: 1694.
15. Shindoh J, Sugawara Y, Akamatsu N, et al,. Thrombotic microangiopathy after living-donor liver transplantation. Am J Transplant 2012; 12: 728.
16. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
17. Yao FY, Ferrell L, Bass NM, et al,. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
18. Sugawara Y, Tamura S, Makuuchi M,. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310.
19. Hakamada K, Kimura N, Miura T, et al,. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1370.
20. Kim do Y, Paik YH, Ahn SH, et al,. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007; 72 (Suppl. 1): 52.
21. Nanashima A, Morino S, Yamaguchi H, et al,. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003; 29: 735.
22. Shimada M, Takenaka K, Fujiwara Y, et al,. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78: 2094.
23. Kobayashi M, Ikeda K, Kawamura Y, et al,. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571.
24. Tateishi R, Shiina S, Yoshida H, et al,. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006; 44: 1518.
25. Kishi K, Sonomura T, Mitsuzane K, et al,. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiat Med 1992; 10: 189.
26. Minakuchi K, Murata K, Kaminoh T, et al,. Clinical evaluation of serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels in patients with hepatocellular carcinoma following interventional radiology. Radiat Med 1993; 11: 231.
27. Koike Y, Shiratori Y, Sato S, et al,. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561.
28. Suehiro T, Matsumata T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K,. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995; 117: 682.
29. Okuda H, Nakanishi T, Takatsu K, et al,. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544.
30. Gomez D, Farid S, Malik HZ, et al,. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757.
31. Chun JM, Kwon HJ, Sohn J, et al,. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 2011; 103: 148.
32. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y,. Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma. Anticancer Res 2013; 33: 1181.
33. Limaye AR, Clark V, Soldevila-Pico C, et al,. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res 2012; 43: 757.
34. An HJ, Jang JW, Bae SH, et al,. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012; 18: 1406.